Analysis of clinically relevant mutations of donors of BKZ-7, -8, and -9, which were inoperable, revealed an epidermal growth factor receptor (EGFR) mutation for the tumor tissue of the donor of BKZ-7, with no mutation for KRAS proto-oncogene (KRAS), B-Raf proto-oncogene (BRAF), or serine/threonine kinase 11 (STK11). This evidence concerns the gene KRAS and neoplasm.